Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry
- 21 August 2003
- journal article
- Published by Elsevier BV in Journal of Chromatography A
- Vol. 1020 (1), 27-34
- https://doi.org/10.1016/s0021-9673(03)00775-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2002
- High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2002
- Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatographyJournal of Chromatography B, 2002
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Role of red blood cells in pharmacokinetics of chemotherapeutic agentsAnti-Cancer Drugs, 1999
- Activated oxazaphosphorines are transported predominantly by erythrocytesAnnals Of Oncology, 1997
- Partitioning of Ifosfamide and Its Metabolites between Red Blood Cells and PlasmaJournal of Pharmaceutical Sciences, 1996
- Preferential location of circulating activated cyclophosphamide within the erythrocyteInternational Journal of Cancer, 1996
- Erythrocytes and the Transport of Drugs and Endogenous CompoundsPharmaceutical Research, 1996
- Description of an instrument for separation of red cells from plasma and measurement of red cell volumeClinical Biochemistry, 1994